JP2017155056A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017155056A5 JP2017155056A5 JP2017111625A JP2017111625A JP2017155056A5 JP 2017155056 A5 JP2017155056 A5 JP 2017155056A5 JP 2017111625 A JP2017111625 A JP 2017111625A JP 2017111625 A JP2017111625 A JP 2017111625A JP 2017155056 A5 JP2017155056 A5 JP 2017155056A5
- Authority
- JP
- Japan
- Prior art keywords
- moiety
- compstatin analog
- peg
- formula
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019129901A JP6905554B2 (ja) | 2011-05-11 | 2019-07-12 | 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161484836P | 2011-05-11 | 2011-05-11 | |
| US61/484,836 | 2011-05-11 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014510520A Division JP6522337B2 (ja) | 2011-05-11 | 2012-05-11 | 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019129901A Division JP6905554B2 (ja) | 2011-05-11 | 2019-07-12 | 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017155056A JP2017155056A (ja) | 2017-09-07 |
| JP2017155056A5 true JP2017155056A5 (enExample) | 2019-09-05 |
| JP6653294B2 JP6653294B2 (ja) | 2020-02-26 |
Family
ID=47139714
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014510520A Active JP6522337B2 (ja) | 2011-05-11 | 2012-05-11 | 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用 |
| JP2017111625A Active JP6653294B2 (ja) | 2011-05-11 | 2017-06-06 | 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用 |
| JP2019129901A Active JP6905554B2 (ja) | 2011-05-11 | 2019-07-12 | 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014510520A Active JP6522337B2 (ja) | 2011-05-11 | 2012-05-11 | 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019129901A Active JP6905554B2 (ja) | 2011-05-11 | 2019-07-12 | 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US10125171B2 (enExample) |
| EP (2) | EP4105224A1 (enExample) |
| JP (3) | JP6522337B2 (enExample) |
| CN (2) | CN103687867B (enExample) |
| AU (3) | AU2012253294B2 (enExample) |
| BR (1) | BR112013028816B1 (enExample) |
| CA (1) | CA2835627C (enExample) |
| DK (1) | DK2707384T3 (enExample) |
| ES (1) | ES2915265T3 (enExample) |
| IL (3) | IL265344B2 (enExample) |
| MX (2) | MX356528B (enExample) |
| RU (1) | RU2653439C9 (enExample) |
| WO (1) | WO2012155107A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| EP2461241A1 (en) | 2010-12-03 | 2012-06-06 | Research In Motion Limited | Soft key with main function and logically related sub-functions for touch screen device |
| RU2653439C9 (ru) | 2011-05-11 | 2018-10-16 | Апеллис Фармасьютикалс, Инк. | Клеточно-реактивные аналоги компстатина, аналоги компстатина длительного действия или аналоги компстатина нацеленного действия и их применение |
| US10035822B2 (en) * | 2012-11-15 | 2018-07-31 | Apellis Pharmaceuticals, Inc. | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
| WO2014078622A1 (en) * | 2012-11-15 | 2014-05-22 | The Brigham And Women's Hospital, Inc. | Method and system for diagnosing and treating preeclampsia |
| WO2014152391A1 (en) * | 2013-03-15 | 2014-09-25 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
| WO2016138520A1 (en) * | 2015-02-27 | 2016-09-01 | The Johns Hopkins University | Assay to diagnose and treat disorders of the alternative pathway of complement activation |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| WO2017035409A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| KR20180090785A (ko) * | 2015-10-07 | 2018-08-13 | 아펠리스 파마슈티컬스 인코포레이티드 | 투여 요법 |
| US10441548B2 (en) | 2015-11-12 | 2019-10-15 | Graybug Vision, Inc. | Aggregating microparticles for medical therapy |
| CN105777893B (zh) * | 2016-03-24 | 2019-10-25 | 杭州亚慧生物科技有限公司 | 一种高强度血清白蛋白骨修复材料及其制备方法 |
| EP3526328A4 (en) * | 2016-10-17 | 2020-05-27 | Apellis Pharmaceuticals, Inc. | COMBINATION THERAPY FOR C3 INHIBITION |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| CA3053818A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders |
| BR112019020955A2 (pt) | 2017-04-07 | 2020-05-05 | Apellis Pharmaceuticals, Inc. | regimes de dosagem e composições e métodos relacionados |
| MX2019013363A (es) | 2017-05-10 | 2020-01-13 | Graybug Vision Inc | Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica. |
| WO2019028284A1 (en) | 2017-08-02 | 2019-02-07 | Achillion Pharmaceuticals, Inc. | THERAPEUTIC REGIMES FOR THE TREATMENT OF NOCTURNAL PAROXYSTIC HEMOGLOBINURIA |
| CN107722262B (zh) * | 2017-09-18 | 2020-11-24 | 华南理工大学 | 一种聚碳二亚胺类聚合物及其制备方法与应用 |
| JP2021507884A (ja) | 2017-12-15 | 2021-02-25 | アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 投与レジメンならびに関連組成物および方法 |
| HUE057693T2 (hu) | 2018-04-06 | 2022-05-28 | Univ Pennsylvania | Fokozott oldhatóságú és javított farmakokinetikai tulajdonságú kompsztatin analógok |
| EP3841086B1 (en) | 2018-08-20 | 2025-04-23 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement factor d medical disorders |
| JP7443375B2 (ja) | 2018-09-06 | 2024-03-05 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 医学的障害の治療のための大環状化合物 |
| WO2020051538A1 (en) | 2018-09-06 | 2020-03-12 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor d inhibitors |
| WO2020069024A1 (en) | 2018-09-25 | 2020-04-02 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor d inhibitors |
| CN113195472A (zh) | 2018-12-17 | 2021-07-30 | 艾其林医药公司 | 用于治疗补体介导的病症的靶向给药 |
| MX2021011507A (es) | 2019-03-22 | 2021-12-15 | Achillion Pharmaceuticals Inc | Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento. |
| US11510939B1 (en) | 2019-04-19 | 2022-11-29 | Apellis Pharmaceuticals, Inc. | RNAs for complement inhibition |
| CN110624274B (zh) * | 2019-08-27 | 2021-04-13 | 苏州赛分科技有限公司 | 分离介质及其制备方法和应用 |
| JP2023515073A (ja) | 2020-02-20 | 2023-04-12 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 補体因子ｄ媒介障害の処置用のヘテロアリール化合物 |
| CA3193488A1 (en) | 2020-09-23 | 2022-03-31 | Jason Allan Wiles | Pharmaceutical compounds for the treatment of complement mediated disorders |
| WO2023081318A2 (en) * | 2021-11-03 | 2023-05-11 | Apellis Pharmaceuticals, Inc. | Complement inhibitor dosing regimens |
| CN118812653A (zh) * | 2023-04-18 | 2024-10-22 | 成都奥达生物科技有限公司 | 一种长效坎普他汀化合物 |
| WO2025176843A1 (en) | 2024-02-21 | 2025-08-28 | Ags Therapeutics Sas | Microalgae extracellular vesicle based gene therapy vectors (mev-gtvs), their preparation, and uses thereof |
| WO2026083442A1 (en) | 2024-10-15 | 2026-04-23 | Mylan Laboratories Limited | Process for the preparation of pegcetacoplan and its purification using chromatography |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2295746A1 (fr) | 1974-12-23 | 1976-07-23 | Francaise Coop Pharma | Nouveaux derives du tryptophane a activite nerveuse centrale renforcee |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| IT1179866B (it) | 1984-12-12 | 1987-09-16 | Rotta Research Lab | Derivati del triptofano farmaceuticamente attivi e composizioni farmaceutiche che li contengono |
| US4576750A (en) | 1985-04-22 | 1986-03-18 | Merck & Co., Inc. | Tryptophan derivative |
| EP0512733A2 (en) | 1991-05-03 | 1992-11-11 | Washington University | Modified complement system regulator |
| US5776970A (en) | 1994-04-28 | 1998-07-07 | Yeda Research And Development Co. Ltd. | Tryptophan derivatives as protein tyrosine kinase blockers and their use in the treatment of neoplastic diseases |
| JP2000505068A (ja) | 1996-03-13 | 2000-04-25 | トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア | 補体活性化を阻害する新規ペプチド類 |
| EP0973551A2 (en) | 1997-04-11 | 2000-01-26 | Advanced Medicine, Inc. | Polymeric conjugates polyvalently presenting an agent for therapy |
| WO1998047002A2 (en) | 1997-04-11 | 1998-10-22 | Advanced Medicine, Inc. | Polyvalent presenter combinatorial libraries and their uses |
| US6169057B1 (en) | 1997-09-04 | 2001-01-02 | The Regents Of The University Of California | Use of tryptophan and analogs as plant growth regulators |
| US6214790B1 (en) | 1998-04-10 | 2001-04-10 | Mayo Foundation For Medical Education And Research | Neo-tryptophan |
| US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
| US7989589B2 (en) | 2002-09-20 | 2011-08-02 | The Trustees Of The University Of Pennsylvania | Compstatin analogs with improved activity |
| CN101325963B (zh) * | 2005-10-08 | 2016-01-27 | 博泰迪亚制药公司 | 用于眼部病症的补体抑制素和其类似物 |
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| WO2007047626A1 (en) | 2005-10-14 | 2007-04-26 | Alcon, Inc. | Combination treatment with anecortave acetate and bevacizumab or ranibizumab for pathologic ocular angiogenesis |
| DK2500030T4 (en) * | 2005-11-04 | 2018-10-29 | Genentech Inc | Use of complement pathway inhibitors for the treatment of eye diseases |
| ES2390828T3 (es) * | 2005-11-28 | 2012-11-16 | The Trustees Of The University Of Pennsylvania | Análogos potentes de la compstatina |
| CL2007003044A1 (es) | 2006-10-24 | 2008-07-04 | Wyeth Corp | Compuestos derivados de benzoxazina; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno psicotico, bipolar, depresivo y abuso o dependencia de sustancias entre otros. |
| EP2148691B1 (en) | 2007-02-05 | 2015-05-20 | Apellis Pharmaceuticals, Inc. | Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system |
| CN101795695B (zh) | 2007-07-19 | 2016-01-06 | 阿列克斯塞尔公司 | 作为抗癌剂的自组装的两亲性聚合物 |
| US20110092446A1 (en) | 2007-07-20 | 2011-04-21 | Cedric Francois | Compositions and methods for treatment of trauma |
| CA2701470A1 (en) | 2007-10-02 | 2009-04-09 | Potentia Pharmaceuticals, Inc. | Sustained delivery of compstatin analogs from gels |
| WO2009121065A2 (en) | 2008-03-28 | 2009-10-01 | Apellis Ag | Modulation and repletion/enhancement of the complement system for treatment of trauma |
| CA2760839C (en) | 2009-05-01 | 2019-02-12 | The Trustees Of The University Of Pennsylvania | Modified compstatin with peptide backbone and c-terminal modifications |
| US9291622B2 (en) | 2009-05-21 | 2016-03-22 | Apellis Pharmaceuticals, Inc. | Complement assays and uses thereof |
| EP2338520A1 (de) | 2009-12-21 | 2011-06-29 | Ludwig Maximilians Universität | Konjugat mit Zielfindungsligand und dessen Verwendung |
| US8625635B2 (en) | 2010-04-26 | 2014-01-07 | Cleversafe, Inc. | Dispersed storage network frame protocol header |
| US9421240B2 (en) | 2010-06-22 | 2016-08-23 | Apellis Pharmaceuticals, Inc. | Compstatin analogs for treatment of neuropathic pain |
| WO2012006599A2 (en) | 2010-07-09 | 2012-01-12 | Apellis Pharmaceuticals, Inc. | Compstatin analogs for treatment of rhinosinusitis and nasal polyposis |
| CA2813049A1 (en) | 2010-09-23 | 2012-03-29 | The Trustees Of The University Of Pennsylvania | Modified compstatin with improved stability and binding properties |
| RU2653439C9 (ru) | 2011-05-11 | 2018-10-16 | Апеллис Фармасьютикалс, Инк. | Клеточно-реактивные аналоги компстатина, аналоги компстатина длительного действия или аналоги компстатина нацеленного действия и их применение |
| CA2840270C (en) | 2011-06-22 | 2023-09-26 | Apellis Pharmaceuticals, Inc. | Methods of treating chronic disorders with complement inhibitors |
| PL2753636T3 (pl) | 2011-09-07 | 2020-05-18 | The Trustees Of The University Of Pennsylvania | Analogi kompstatyny o ulepszonych właściwościach farmakokinetycznych |
| WO2014028861A1 (en) | 2012-08-17 | 2014-02-20 | Apellis Pharmaceuticals, Inc. | Detection of high risk drusen |
| WO2014078734A2 (en) | 2012-11-15 | 2014-05-22 | Apellis Pharmaceuticals, Inc. | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
| US10035822B2 (en) | 2012-11-15 | 2018-07-31 | Apellis Pharmaceuticals, Inc. | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
| WO2014100407A1 (en) | 2012-12-19 | 2014-06-26 | The Regents Of The University Of California | Compstatin analogs |
| WO2014152391A1 (en) | 2013-03-15 | 2014-09-25 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
| US9566459B2 (en) | 2013-07-16 | 2017-02-14 | Beijing Mechanical Equipment Institute | Fire engine suitable for fire-fighting in high-rise and super high-rise buildings |
| US9806963B2 (en) | 2013-10-18 | 2017-10-31 | Cellco Partnership | Feature activation on device |
| BR112019020955A2 (pt) | 2017-04-07 | 2020-05-05 | Apellis Pharmaceuticals, Inc. | regimes de dosagem e composições e métodos relacionados |
-
2012
- 2012-05-11 RU RU2013149956A patent/RU2653439C9/ru active
- 2012-05-11 US US14/116,591 patent/US10125171B2/en active Active
- 2012-05-11 CN CN201280033181.7A patent/CN103687867B/zh active Active
- 2012-05-11 CN CN201611160681.3A patent/CN107050422B/zh active Active
- 2012-05-11 IL IL265344A patent/IL265344B2/en unknown
- 2012-05-11 EP EP22159092.0A patent/EP4105224A1/en active Pending
- 2012-05-11 ES ES12782170T patent/ES2915265T3/es active Active
- 2012-05-11 BR BR112013028816-7A patent/BR112013028816B1/pt active IP Right Grant
- 2012-05-11 JP JP2014510520A patent/JP6522337B2/ja active Active
- 2012-05-11 DK DK12782170.0T patent/DK2707384T3/da active
- 2012-05-11 EP EP12782170.0A patent/EP2707384B1/en active Active
- 2012-05-11 CA CA2835627A patent/CA2835627C/en active Active
- 2012-05-11 MX MX2013013084A patent/MX356528B/es active IP Right Grant
- 2012-05-11 MX MX2018006699A patent/MX385001B/es unknown
- 2012-05-11 WO PCT/US2012/037648 patent/WO2012155107A1/en not_active Ceased
- 2012-05-11 AU AU2012253294A patent/AU2012253294B2/en active Active
-
2013
- 2013-11-11 IL IL229368A patent/IL229368B/en active IP Right Grant
-
2017
- 2017-06-06 JP JP2017111625A patent/JP6653294B2/ja active Active
- 2017-10-11 AU AU2017245334A patent/AU2017245334B2/en active Active
-
2018
- 2018-10-10 US US16/157,052 patent/US11001610B2/en active Active
-
2019
- 2019-07-12 JP JP2019129901A patent/JP6905554B2/ja active Active
- 2019-09-05 AU AU2019226186A patent/AU2019226186B2/en active Active
-
2021
- 2021-03-17 US US17/204,742 patent/US11661441B2/en active Active
-
2023
- 2023-04-11 US US18/133,372 patent/US20240076317A1/en not_active Abandoned
- 2023-07-06 IL IL304291A patent/IL304291A/en unknown
-
2025
- 2025-06-05 US US19/229,679 patent/US20260062448A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2397852T3 (es) | Antagonistas y conjugados de péptidos CGRP | |
| ES2703110T3 (es) | Composiciones y métodos de uso de péptidos de neogénesis insular y análogos de los mismos | |
| JP6525471B2 (ja) | ヘプシジン類似体及びその使用 | |
| JP2022514618A5 (enExample) | ||
| JP2019206547A5 (enExample) | ||
| US11884747B2 (en) | Compstatin analogs with increased solubility and improved pharmacokinetic properties | |
| JP2011511778A5 (enExample) | ||
| JP2014514364A5 (enExample) | ||
| EP3749345A1 (en) | Conjugated hepcidin mimetics | |
| JP2017523959A (ja) | ヘプシジンおよびミニ−ヘプシジンアナログおよびその使用 | |
| RU2010103995A (ru) | Бифункциональные слитые белки альфа-меланоцитостимулирующего гормона (альф-msh) и атриального натрийуретического белка (anp) и их применение при гипертонии и остром повреждении почек | |
| AR106920A1 (es) | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia linfocítica crónica (llc) y otros tipos de cáncer | |
| ES2692722T3 (es) | Composición de recubrimiento de microagujas y dispositivo de microagujas | |
| JP2009532384A5 (enExample) | ||
| TW201028162A (en) | Amide based glucagon superfamily peptide prodrugs | |
| AR105817A1 (es) | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer | |
| WO2012065751A1 (en) | Bio-functionalized stimulus-responsive dissolvable peg-hydrogels | |
| JP2011511753A5 (enExample) | ||
| JP2019501867A5 (enExample) | ||
| TW201209062A (en) | Amide based glucagon superfamily peptide prodrugs | |
| RU2014117678A (ru) | Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью | |
| JP2013543497A5 (enExample) | ||
| JP2015532283A5 (enExample) | ||
| RU2018116446A (ru) | Схемы введения | |
| RU2013146690A (ru) | Циклические пептиды с антинеопластической и антиангионенной активностью |